A Clinical Trial About Treatment of Mild to Moderate Persistent Alergic Rhinnitis With Test or Reference Mometasone (PUMA)
A Phase III, Non-inferiority, Open-label, Multicenter and Randomized Clinical Trial About the Treatment of Mild to Moderate Persistent Allergic Rhinitis With Eurofarma Mometasone or Reference Mometasone.
Sponsor: Eurofarma Laboratorios S.A.
Listed as NCT01372865, this PHASE3 trial focuses on Mild to Moderate Persistent Allergic Rhinitis and remains completed. Sponsored by Eurofarma Laboratorios S.A., it has been updated 7 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Jan 2017 — Oct 2017 [monthly]
Unknown Status PHASE3
First recorded
Jun 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eurofarma Laboratorios S.A.
For direct contact, visit the study record on ClinicalTrials.gov .